AccuGenomics Inc is pleased to announce that it has joined the FNIH Biomarkers Consortium focused on Measurable residual disease in acute myeloid leukemia (MRD in AML). We look forward to our participation in advancing the accuracy of targeted NGS testing of liquid biopsy samples.As a disruptive precision diagnostics technology company, AccuGenomics’s mission is to improve the accuracy and performance of…